Pharmaceuticals Europe

Europe Migraine Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe Migraine Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.59 Bn Placeholder estimate
Estimate 2025 $1.69 Bn 19.3% of the global market
Projected 2034 $2.96 Bn 74.8% Adds $1.26 Bn over 9 forecast years
CAGR 2025–2034 6.4% Faster than 45% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Europe is 19.33% of the global market.
  • Among regions, the largest is North America at $4.84 Bn.
  • Fastest growing: Africa at 9.5% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.26 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Migraine Drugs Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.59 Bn — —
2025 (base) $1.69 Bn +$101.7 Mn —
2026 (forecast) $1.80 Bn +$108.2 Mn +6.4%
2027 (forecast) $1.91 Bn +$115.2 Mn +13.2%
2028 (forecast) $2.04 Bn +$122.5 Mn +20.5%
2029 (forecast) $2.17 Bn +$130.4 Mn +28.2%
2030 (forecast) $2.31 Bn +$138.7 Mn +36.4%
2031 (forecast) $2.45 Bn +$147.6 Mn +45.1%
2032 (forecast) $2.61 Bn +$157.0 Mn +54.4%
2033 (forecast) $2.78 Bn +$167.1 Mn +64.3%
2034 (forecast) $2.96 Bn +$177.8 Mn +74.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Migraine Drugs Market Analysis at a glance
Market size, 2025$1.69 Bn placeholder estimate
Forecast, 2034$2.96 Bn placeholder estimate
Growth (CAGR), 2025–20346.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, use and end user (see all)
Key playersPfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and 1 more (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials69 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Migraine Drugs Market Analysis Executive Summary

Migraine drugs stop or prevent migraine attacks, including newer CGRP-blocking medicines and triptans.

Key segments of the migraine Drugs market include drug class (CGRP Antibodies, Gepants and Triptans) and use (Acute Treatment and Prevention).

Bar chart: Europe Migraine Drugs market size, 2024–2034, placeholder estimates. $1.59 Bn in 2024, $1.69 Bn in 2025 and $2.96 Bn in 2034, 6.4% CAGR.
Europe Migraine Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Migraine Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the migraine Drugs market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the migraine Drugs market.

Competitive Landscape for Migraine Drugs Market in Europe

The migraine Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Migraine Drugs Market in Europe

Migraine Drugs in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], CBG-MEB (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15] ClinicalTrials.gov lists 69 studies on Migraine Drugs that are recruiting, active or about to start in Europe.⁠[16]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.

[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.

[10] Swissmedic. Checked 19 Nov 2026.

[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.

[12] Danish Medicines Agency. Checked 19 Nov 2026.

[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.

[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.

[15] European Commission, health technology assessment. Checked 14 Nov 2026.

[16] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for migraine Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Migraine Drugs right now, from free public sources.

Clinical trials

69 active trials in UK, Germany, France, Italy, Spain, Netherlands, Belgium, Switzerland, Sweden, Denmark, Poland, Turkey and Russia

Recruiting, about to start, or running now. Counted across the 13 countries we report on in Europe.

Top trial sponsors (worldwide)

  1. Pfizer Inc. 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. AbbVie Inc. 11 active trials on ClinicalTrials.gov (opens in a new tab)
  3. TriGemX Bio, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Ipsen 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Lundbeck 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Migraine Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Migraine Drugs market in Europe?
Placeholder estimate: about $1.69 Bn in 2025, rising to about $2.96 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Migraine Drugs market in Europe growing?
Placeholder estimate: about 6.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Migraine Drugs market report cover?
The report splits the market by drug class (CGRP Antibodies, Gepants, Triptans, Ditans and more), use (Acute Treatment, Prevention) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Migraine Drugs market?
Key players include Pfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and Lundbeck.
What is driving the Migraine Drugs market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.
Who regulates Migraine Drugs in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Migraine Drugs are running in Europe?
69 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Migraine Drugs?
PubMed lists 60 papers on Migraine Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on brain and nerves and pain

See the topic